(Z)-3-benzylidene-1-oxo-2,3-dihydroisoindole-2-acetic acid | 71898-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (Z)-3-benzylidene-1-oxo-2,3-dihydroisoindole-2-acetic acid
• 英文别名: (Z)-2-(3-benzylidene-1-oxoisoindolin-2-yl)acetic acid；2-[(1Z)-1-benzylidene-3-oxoisoindol-2-yl]acetic acid
• CAS: 71898-26-5
• 化学式: C₁₇H₁₃NO₃
• 分子量: 279.295
• InChiKey: KMZIHUBNZPYQPT-GDNBJRDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-3-benzylidene-1-oxo-2,3-dihydroisoindole-2-acetic acid 在 tetraphosphorus decasulfide 、 硫酸 、 一水合肼 作用下， 以 吡啶 、 乙醇 为溶剂， 反应 11.5h， 生成 (Z)-6-benzylidene-3-oxo-2,3,4,6-tetrahydro<1,2,4>triazino<3,4-a>indole
  参考文献：
  名称：

  A New Synthesis of Fused 1,2,4-Triazine Derivatives

  摘要：

  DOI：

  10.1055/s-1982-29972
• 作为产物：
  描述：

  (E)-2-(3-benzylidene-1-oxoisoindolin-2-yl)acetic acid 、 盐酸 生成 (Z)-3-benzylidene-1-oxo-2,3-dihydroisoindole-2-acetic acid
  参考文献：
  名称：

  SCARTONI V.; FIASCHI R.; CATALANO S.; MORELLI I.; MARSILI A., J. CHEM. SOC. PERKIN TRANS., PART 1, 1979, NO 6, 1547-1551

  摘要：

  DOI：

文献信息

• Dipeptidyl peptidase-IV inhibitors
  申请人：Hulin Bernard

  公开号：US20050234065A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R 1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

  该发明提供了Formula (I)的化合物或其前药，或者该化合物或前药的药用可接受盐，或者该化合物、前药或盐的溶剂化合物，其中A、N、X和R1如本文所定义；以及这些药物组合物；以及使用这些药物组合物治疗疾病的方法，包括2型糖尿病、1型糖尿病、糖耐量受损、高血糖、代谢综合征（综合征X和/或胰岛素抵抗综合征）、葡萄糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病神经病、糖尿病肾病、糖尿病视网膜病、糖尿病心肌病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱、骨质流失、骨折、急性冠状动脉综合征、生长激素缺乏引起的矮小症、多囊卵巢综合征引起的不孕症、焦虑、抑郁、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动相关的疾病、溃疡、肠易激综合征、炎症性肠病；短肠综合征；以及预防2型糖尿病疾病进展。
• Unprecedented Alkene Transposition in Phthalate–Amino Acid Adducts
  作者：Ian Baxendale、Marcus Baumann、Ishika Saha

  DOI：10.1055/s-0037-1611294

  日期：2018.12

  on the outcome of the thermal reaction between benzylidene phthalides and various amino acid derivatives is reported. It was discovered that the tricyclic pyrroles as previously described are not the products formed in these reactions. Instead under high-temperature conditions decarboxylated phthalamide adducts are formed within 5-10 minutes. Additionally, an unprecedented alkene transposition mechanism

  详细说明了苯亚甲基苯酞和各种氨基酸衍生物之间的热反应结果。发现如前所述的三环吡咯不是这些反应中形成的产物。相反，在高温条件下，脱羧邻苯二甲酰胺加合物会在 5-10 分钟内形成。此外，已经确定了一种前所未有的烯烃转座机制，导致这些反应的最终产物。
• DEODHAR, K. D.;DSA, A. D.;PEDNEKAR, S. R.;KANEKAR, D. S., SYNTHESIS, BRD, 1982, N 10, 853-854
  作者：DEODHAR, K. D.、DSA, A. D.、PEDNEKAR, S. R.、KANEKAR, D. S.

  DOI：——

  日期：——
• [EN] DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDYL PEPTIDASE-IV
  申请人：PFIZER PROD INC

  公开号：WO2005100334A1

  公开（公告）日：2005-10-27

  The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.
• A New Synthesis of Fused 1,2,4-Triazine Derivatives
  作者：K. D. Deodhar、A. D. D'Sa、S. R. Pednekar、D. S. Kanekar

  DOI：10.1055/s-1982-29972

  日期：——